title: Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men.
abstract: We defined risk factors for a clinical diagnosis of benign prostatic hyperplasia (BPH) among subjects of the population-based Massachusetts Male Aging Study. In 1987-89 1709 men aged 40-70 provided baseline risk factor data and were followed for a mean of 9 years; 1019 men without prostate cancer provided follow-up data. We classified men with clinical BPH at follow-up if they reported (1) frequent or difficulty urinating and were told by a health professional that they had an enlarged or swollen prostate or (2) if they reported having surgery for BPH. At follow-up the prevalence of clinical BPH was 19.4%, increasing from 8.4% of men aged 38-49 years to 33.5% of men aged 60-70 years (P < 0.001 for trend). Elevated free PSA levels (age- and total PSA-adjusted OR, top vs. bottom quartile ng/mL 4.4, 95% CI 1.9-10.5), heart disease (age-adjusted OR 2.1, CI 1.3-3.3), and use of beta-blocker medications (OR 1.8, CI 1.1-3.0) increased odds for BPH, while current cigarette smoking (OR 0.5, CI 0.3-0.8) and high levels of physical activity (top vs. bottom quartile kcals/day OR 0.5, CI 0.3-0.9) decreased odds of BPH. All but the medication effects persisted in fully adjusted multivariable models. Total or fat calorie intake, sexual activity level, alcohol intake, body mass index, waist-hip ratio, diastolic blood pressure, a history of diabetes, hypertension, vasectomy, or serum levels of androgens or estrogens did not individually predict clinical BPH. We conclude that physical exercise and cigarette smoking appear to protect against development of clinical BPH. Elevated free PSA levels predict clinical BPH independent of total PSA levels. Risk associated with heart disease does not appear to be due solely to detection bias or to effects of heart disease medications. A wide variety of other characteristics appear to have no influence on risk for clinical BPH.
authors.affiliation: General Medicine Unit, Medical Services, Massachusetts General Hospital and Harvard Medical School, 50 Staniford Street, Boston, MA 02114, USA. jmeigs@partners.org
authors.forename: J B
authors.initials: JB
authors.lastname: Meigs
authors.forename: B
authors.initials: B
authors.lastname: Mohr
authors.forename: M J
authors.initials: MJ
authors.lastname: Barry
authors.forename: M M
authors.initials: MM
authors.lastname: Collins
authors.forename: J B
authors.initials: JB
authors.lastname: McKinlay
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000375:Aging; D003625:Data Collection; D006801:Humans; D008297:Male; D008404:Massachusetts / Q000453:epidemiology; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000453:epidemiology* / Q000209:etiology; D012307:Risk Factors
chemical_list: D017430:Prostate-Specific Antigen